Social and Behavioral Sciences Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Am J Epidemiol. 2020 Jan 31;189(1):1-5. doi: 10.1093/aje/kwz214.
The developmental origins of health and disease (DOHaD) model promises a greater understanding of early development but has left unresolved the balance of risks and benefits to offspring of medication use during pregnancy. Masarwa et al. (Am J Epidemiol. 2018;187(8):1817-1827) conducted a meta-analysis of the association between in utero acetaminophen exposure and risks of attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). A challenge of meta-analyzing results from observational studies is that summary measures of risk do not correspond to well-defined interventions when the individual studies adjusted for different covariate sets, which was the case here. This challenge limits the usefulness of observational meta-analyses for inferences about etiology and treatment planning. With that limitation understood, Masarwa et al. reported a 20%-30% higher risk of ADHD and ASD following prenatal acetaminophen exposure. Surprisingly, most of the original studies did not report diagnoses of ADHD or ASD. As a result, their summary estimates of risk are not informative about children's likelihood of ADHD and ASD diagnoses. The long-term promise of DOHaD remains hopeful, but more effort is needed in the short-term to critically evaluate observational studies suggesting risks associated with medications used to treat conditions during pregnancy that might have adverse consequences for a developing fetus.
健康与疾病的发育起源(DOHaD)模型有望更深入地了解早期发育,但对于在怀孕期间使用药物对后代的风险和益处的平衡问题仍未解决。Masarwa 等人(Am J Epidemiol. 2018;187(8):1817-1827)对胎儿期乙酰氨基酚暴露与注意力缺陷多动障碍(ADHD)和自闭症谱系障碍(ASD)风险之间的关联进行了荟萃分析。当个体研究针对不同的协变量集进行调整时,对观察性研究结果进行荟萃分析的一个挑战是,风险的汇总度量与明确定义的干预措施不对应,在这种情况下就是如此。当了解到这一限制后,Masarwa 等人报告称,产前使用乙酰氨基酚会使 ADHD 和 ASD 的风险增加 20%-30%。令人惊讶的是,大多数原始研究并未报告 ADHD 或 ASD 的诊断。因此,他们对风险的汇总估计并不能说明儿童患 ADHD 和 ASD 的可能性。DOHaD 的长期前景仍然充满希望,但在短期内需要付出更多努力来批判性地评估那些提示与怀孕期间用于治疗疾病的药物相关风险的观察性研究,这些风险可能对发育中的胎儿产生不利影响。